Literature DB >> 25381321

The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia.

Emilio Bouza1, Martha Kestler2, Teresa Beca3, Gabriel Mariscal3, Marta Rodríguez-Créixems3, Javier Bermejo4, Ana Fernández-Cruz3, Francisco Fernández-Avilés4, Patricia Muñoz1.   

Abstract

BACKGROUND: Frequency of enterococcal bloodstream infection (E-BSI) is increasing, and the number of episodes complicated by infective endocarditis (IE) varies. Performing transesophageal echocardiography (TEE) in all patients with E-BSI is costly and time-consuming. Our objectives were to identify patients with E-BSI who are at very low risk of enterococcal IE (and therefore do not require TEE) and to compare the outcome of E-BSI in patients with/without IE.
METHODS: Between September 2003 and October 2012, we performed a prospective cohort study (all patients with E-BSI) and a case-control study (patients with/without enterococcal IE) in our center.
RESULTS: We detected 1515 patients with E-BSI and 65 with enterococcal IE (4.29% of all episodes of E-BSI, 16.7% of patients with E-BSI who underwent transthoracic echocardiography, and 35.5% of all patients with E-BSI who underwent TEE). We developed a bedside predictive score for enterococcal IE-Number of positive blood cultures, Origin of the bacteremia, previous Valve disease, Auscultation of heart murmur (NOVA) score-based on the following variables: Number of positive blood cultures (3/3 blood cultures or the majority if more than 3), 5 points; unknown Origin of bacteremia, 4 points; prior heart Valve disease, 2 points; Auscultation of a heart murmur, 1 point (receiver operating characteristic = 0.83). The best cutoff corresponded to a score ≥4 (sensitivity, 100%; specificity, 29%). A score <4 points suggested a very low risk for enterococcal IE and that TEE could be obviated.
CONCLUSIONS: Enterococcal IE may be more frequent than generally thought. Depending on local prevalence of endocarditis, application of the NOVA score may safely obviate echocardiography in 14%-27% of patients with E-BSI.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Enterococcus spp.; bacteremia; endocarditis

Mesh:

Year:  2014        PMID: 25381321     DOI: 10.1093/cid/ciu872

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Automatic Digital Analysis of Chromogenic Media for Vancomycin-Resistant-Enterococcus Screens Using Copan WASPLab.

Authors:  Matthew L Faron; Blake W Buchan; Christopher Coon; Theo Liebregts; Anita van Bree; Arjan R Jansz; Genevieve Soucy; John Korver; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

2.  Marseille scoring system for empiric treatment of infective endocarditis.

Authors:  Frédérique Gouriet; Hervé Tissot-Dupont; Jean-Paul Casalta; Sandrine Hubert; Pierre-Edouard Fournier; Sophie Edouard; Alexis Theron; Hubert Lepidi; Dominique Grisoli; Gilbert Habib; Didier Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-03       Impact factor: 3.267

3.  The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary.

Authors:  Andreas Berge; Andrea Krantz; Helena Östlund; Pontus Nauclér; Magnus Rasmussen
Journal:  Infection       Date:  2018-09-03       Impact factor: 3.553

4.  Short time to blood culture positivity in Enterococcus faecalis infective endocarditis.

Authors:  Karl Oldberg; Rebecca Thorén; Bo Nilson; Patrik Gilje; Malin Inghammar; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-09       Impact factor: 3.267

5.  RNA-seq and Tn-seq reveal fitness determinants of vancomycin-resistant Enterococcus faecium during growth in human serum.

Authors:  Xinglin Zhang; Vincent de Maat; Ana M Guzmán Prieto; Tomasz K Prajsnar; Jumamurat R Bayjanov; Mark de Been; Malbert R C Rogers; Marc J M Bonten; Stéphane Mesnage; Rob J L Willems; Willem van Schaik
Journal:  BMC Genomics       Date:  2017-11-21       Impact factor: 3.969

6.  Impact on Mortality of a Bundle for the Management of Enterococcal Bloodstream Infection.

Authors:  Michele Bartoletti; Sara Tedeschi; Luigia Scudeller; Renato Pascale; Elena Rosselli Del Turco; Filippo Trapani; Fabio Tumietto; Giulio Virgili; Lorenzo Marconi; Stefano Ianniruberto; Matteo Rinaldi; Ilaria Contadini; Francesco Cristini; Linda Bussini; Caterina Campoli; Simone Ambretti; Andrea Berlingeri; Pierluigi Viale; Maddalena Giannella
Journal:  Open Forum Infect Dis       Date:  2019-11-04       Impact factor: 3.835

7.  Enterococcal bacteraemia: predictive and prognostic risk factors for ampicillin resistance.

Authors:  T Matsumura; M Nagao; S Nakano; M Yamamoto; Y Matsumura; S Ichiyama
Journal:  Epidemiol Infect       Date:  2018-08-31       Impact factor: 4.434

8.  Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study.

Authors:  Patricia Muñoz; Martha Kestler; Arístides De Alarcon; José María Miro; Javier Bermejo; Hugo Rodríguez-Abella; Maria Carmen Fariñas; Manuel Cobo Belaustegui; Carlos Mestres; Pedro Llinares; Miguel Goenaga; Enrique Navas; José Antonio Oteo; Paola Tarabini; Emilio Bouza
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

9.  Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study.

Authors:  Andreas Berge; Karin Kronberg; Torgny Sunnerhagen; Bo H K Nilson; Christian G Giske; Magnus Rasmussen
Journal:  Open Forum Infect Dis       Date:  2019-10-04       Impact factor: 3.835

10.  Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections.

Authors:  Rachael A Lee; Daniel T Vo; Joanna C Zurko; Russell L Griffin; J Martin Rodriguez; Bernard C Camins
Journal:  Open Forum Infect Dis       Date:  2020-02-19       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.